Botanix Pharmaceuticals Ltd has released a press release.
BOT Submits FDA New Drug Application for Sofpironium Bromide
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Issue of First $7.0m Tranche of A$7.5m Placement Completed
- Botanix Completes Successful A$7.5m Placement
- Preliminary Final Report
- Quarterly activities report and Appendix 4C
- Change of Director's Interest Notice * 3
Later from Botanix Pharmaceuticals
- Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea
- BOT Announces Promotion and Focus on NDA Approval Readiness
- Botanix receives A$3.7m R&D Tax Incentive Refund
- A$5 million Institutional Placement and Share Purchase Plan
- Share Purchase Plan Opens
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals